Mitsubishi Corporation
https://www.mhi-global.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Mitsubishi Corporation
From Inflection To Insight: Vertex And Merck’s Dueling HCV Drugs
Welcome to Inflection to Insight, a new series taking a closer look at notable chapters in biopharma history, gleaning learnings to inform current business strategy. This inaugural instalment looks at the rapid rise and fall of two competing drugs for hepatitis C virus, Vertex’s Incivek and Merck & Co’s Victrelis.
Stalicla Seals Deal To Advance Novartis Drug For Cocaine Misuse
The biotech has persuaded its fellow Swiss firm that it can advance mavoglurant, a Novartis drug that has failed in Parkinson’s and Fragile X syndrome, for cocaine use and neurodevelopmental disorders.
Deal Watch: Aging-Focused Calico Taps Start-Up Terray For Discovery
Terray/Calico tie-up will focus on small molecule discovery for diseases of aging, including cancer. Lilly, AstraZeneca sign discovery pacts with Nimbus and Illumina, respectively.
Japan's Price Cuts Slated For April Bring Old, New Blues For Industry
Next month’s regular reimbursement price cut in Japan includes some large reductions for big-selling drugs, while one new rule has been applied for the first time.
Company Information
- Industry
- Distributors
- Diversified
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Diamond Distributed Energy Investments, LLC
- Japan Medicalnext Co., Ltd.
- MC Healthcare, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice